Letter

Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII

BMJ 1998; 316 doi: 10.1136/bmj.316.7141.1385 (Published 2 May 1998)
Cite this as: BMJ 1998;316:1385.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. J P Betts, International technical affairs director
  1. Grupo Grifols, Cambridge CB4 4GP

    EDITOR—Barbara and Flanagan report the precautionary measures against new variant Creutzfeldt-Jakob disease that have been announced by the UK Department of Health.1 Unfortunately, the secretary of state announced the outcome of the NHS review of the provision of factor VIII for patients with haemophilia at the same time. The rationale for endorsing the use of recombinant factor VIII in children has thus become linked to concerns over new variant Creutzfeldt-Jakob.

    Recombinant factor VIII is a biologically derived product produced by cell culture, not a synthetic product as stated in the announcement …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular